Comparative efficacy and safety of vedolizumab and antitumor necrosis factor alfa in patients with inflammatory bowel diseases: A meta‑analysis
By:
Authors
Yafang Li
Department of Gastroenterology and Hepatology, The Affiliated Jinhua Hospital Zhejiang University School of Medicine, Jinhua, P.R. China
Jin Ding
Department of Gastroenterology and Hepatology, The Affiliated Jinhua Hospital Zhejiang University School of Medicine, Jinhua, P.R. China
Chong Lu
Department of Gastroenterology and Hepatology, The Affiliated Jinhua Hospital Zhejiang University School of Medicine, Jinhua, P.R. China
Yiping Hong
Department of Gastroenterology and Hepatology, The Affiliated Jinhua Hospital Zhejiang University School of Medicine, Jinhua, P.R. China
Qunying Wang
Department of Gastroenterology and Hepatology, The Affiliated Jinhua Hospital Zhejiang University School of Medicine, Jinhua, P.R. China
Language: English
Page range: 23 - 40
Accepted on: Jan 20, 2025
Published on: Apr 10, 2025
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:
© 2025 Yafang Li, Jin Ding, Chong Lu, Yiping Hong, Qunying Wang, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.